Switch theme
Sign up to access all valuation multiples
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. The group is also involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.
1978
4.2K+
LTM Revenue $673M
LTM EBITDA $154M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gland Pharma has a last 12-month revenue (LTM) of $673M and a last 12-month EBITDA of $154M.
In the most recent fiscal year, Gland Pharma achieved revenue of $661M and an EBITDA of $176M.
Gland Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gland Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $673M | XXX | $661M | XXX | XXX | XXX |
| Gross Profit | $423M | XXX | $406M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $154M | XXX | $176M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $114M | XXX | $117M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $86.7M | XXX | $90.5M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Gland Pharma's stock price is INR 1589 (or $19).
Gland Pharma has current market cap of INR 262B (or $3.1B), and EV of INR 236B (or $2.8B).
See Gland Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $3.1B | XXX | XXX | XXX | XXX | $0.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Gland Pharma has market cap of $3.1B and EV of $2.8B.
Gland Pharma's trades at 4.6x EV/Revenue multiple, and 16.5x EV/EBITDA.
Equity research analysts estimate Gland Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gland Pharma has a P/E ratio of 35.4x.
See valuation multiples for Gland Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | 17.9x | XXX | 16.5x | XXX | XXX | XXX |
| EV/EBIT | 24.2x | XXX | 24.3x | XXX | XXX | XXX |
| EV/Gross Profit | 6.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 35.4x | XXX | 33.8x | XXX | XXX | XXX |
| EV/FCF | 51.1x | XXX | 48.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGland Pharma's last 12 month revenue growth is 13%
Gland Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Gland Pharma's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gland Pharma's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Gland Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 41% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gland Pharma acquired XXX companies to date.
Last acquisition by Gland Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Gland Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Gland Pharma founded? | Gland Pharma was founded in 1978. |
| Where is Gland Pharma headquartered? | Gland Pharma is headquartered in India. |
| How many employees does Gland Pharma have? | As of today, Gland Pharma has 4.2K+ employees. |
| Who is the CEO of Gland Pharma? | Gland Pharma's CEO is Mr. Shyamakant Giri. |
| Is Gland Pharma publicy listed? | Yes, Gland Pharma is a public company listed on NSE. |
| What is the stock symbol of Gland Pharma? | Gland Pharma trades under GLAND ticker. |
| When did Gland Pharma go public? | Gland Pharma went public in 2020. |
| Who are competitors of Gland Pharma? | Similar companies to Gland Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Gland Pharma? | Gland Pharma's current market cap is $3.1B |
| What is the current revenue of Gland Pharma? | Gland Pharma's last 12 months revenue is $673M. |
| What is the current revenue growth of Gland Pharma? | Gland Pharma revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Gland Pharma? | Current revenue multiple of Gland Pharma is 4.1x. |
| Is Gland Pharma profitable? | Yes, Gland Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gland Pharma? | Gland Pharma's last 12 months EBITDA is $154M. |
| What is Gland Pharma's EBITDA margin? | Gland Pharma's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Gland Pharma? | Current EBITDA multiple of Gland Pharma is 17.9x. |
| What is the current FCF of Gland Pharma? | Gland Pharma's last 12 months FCF is $54.0M. |
| What is Gland Pharma's FCF margin? | Gland Pharma's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Gland Pharma? | Current FCF multiple of Gland Pharma is 51.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
